Purpose: To report the incidence, demographics, and ocular findings of children with myasthenia Design: Retrospective cohort study Methods: The medical records of all children (< 19 years) examined at Mayo Clinic with any form of myasthenia from January 1 1966, through December 31, 2015, were retrospectively reviewed.Results: A total of 364 children were evaluated during the study period, of which 6 children were residents of the Olmsted County at the time of their diagnosis, yielding an annual age-and sex-adjusted incidence of 0.35 per 100,000 <19 years, or 1 in 285,714 <19 years. The incidence of juvenile myasthenia gravis (JMG) and congenital myasthenic syndrome (CMS) was 0.12 and 0.23 per 100,000, respectively. Of the 364 study children, 217 (59.6%) had JMG, 141 (38.7%) had CMS, and 6 (1.7%) had Lambert-Eaton syndrome, diagnosed at a median age of 13.5, 5.1, and 12.6 years, respectively. A majority of the JMG and CMS patients had ocular involvement (90.3 and 85.1% respectively), including ptosis and ocular movement deficits. Among children with at least one year of follow-up, (JMG; median, 7.1 years, CMS; median, 7.0 years) improvement was seen in 88.8% of JMG patients (complete remission in 31.3%) and in 58.3% of CMS patients.
Conclusion:Although relatively rare, myasthenia gravis in children has two predominant forms, CMS and JMG, both of which commonly have ocular involvement. Improvement is more likely in children with the juvenile form.Myasthenia gravis is a chronic autoimmune disease characterized by fluctuating weakness and fatigability of the voluntary muscles of the body. 1 Pediatric myasthenia is a common term for disease onset prior to 19 years of age and includes both the autoimmune and inherited etiologies. 2 Pediatric myasthenia is divided into neonatal, congenital, and juvenile forms. Congenital myasthenic syndrome includes a diverse group of inherited disorders, typically present at birth, caused by a defective signal transmission at the neuromuscular